Minaxolone (CCI-12923) is a neuroactive steroid which was developed as a general anesthetic but was withdrawn before registration due to toxicity seen with long-term administration in rats, and hence was never marketed.[1][2][3] It is a positive allosteric modulator of the GABAA receptor,[4] as well as, less potently, a positive allosteric modulator of the glycine receptor.[4][5]
Clinical data | |
---|---|
Other names | 11α-(Dimethylamino)-2β-ethoxy-3α-hydroxy-5α-pregnan-20-one |
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
IUPHAR/BPS |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
Chemical and physical data | |
Formula | C25H43NO3 |
Molar mass | 405.623 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |